Skip to main content






Fungal Meningitis Outbreak


FDA provides NECC Customer List

FDA is making available two lists of customers (consignees) who received products that were shipped on or after May 21, 2012 from New England Compounding Center's Framingham, MA facility. The first list includes customer names and addresses, organized by state. The second list contains the same basic information as the first list, but is organized alphabetically by customer name and also includes the specific products shipped, the quantities of product shipped, and the shipping date. The lists were prepared based on information provided by NECC, and FDA cannot vouch for the completeness or accuracy of the lists. Products shipped by NECC may be missing from the list and facility information may be incomplete. Nevertheless, this is the best information we have available, at this time, to help inform facilities and healthcare providers of NECC products shipped to their facilities since May 21, 2012.

FDA is reiterating and updating its previous recommendation that follow-up with patients be done when the following three conditions are met:

* The medication was an injectable product purchased from or produced by NECC, including an ophthalmic drug that is injectable or used in conjunction with eye surgery, or a cardioplegic solution,

* The medication was shipped by NECC on or after May 21, 2012, and

* The medication was administered to patients on or after May 21, 2012.

Since the May 21, 2012 date is the date the first of three lots of methylprednisolone acetate implicated in the current outbreak was produced, products produced and shipped by NECC on or after May 21, 2012 are believed at this time to be of greatest risk of contamination. Now that we have shipping information available, we are updating FDA's recommendation to health care providers so that they can focus their attention on following up with the patients who are believed to be at greatest risk of receiving a contaminated product.

Read the MedWatch Safety Alert, including links to the FDA update and the NECC Customer Lists, at:





FDA重申和更新之前的建議,當病人符合以下三項條件時需密切觀察:1. 藥品為向NECC購買或由其調製之注射劑,包含可用於注射或眼部手術中配合使用之眼用藥品,或心臟麻痺溶液。2. 此藥品為NECC於2012年5月21日(含)以後出貨之產品。3. 病人於2012年5月21日(含)以後使用此藥品。

因2012年5月21日為最先被認為與近期發生之感染有關連之三批methylprednisolone acetate的製造日期,由此之後NECC出貨之產品皆被認為具有相當大的汙染風險。


相關訊息與連結請參考FDA網址: /SafetyAlertsforHumanMedicalProducts/ucm323946.htm
[Posted 10/22/2012]